DEC1 promotes breast cancer bone metastasis through transcriptional activation of CXCR4

Abstract

Bone metastasis is the primary cause of mortality in breast cancer (BC) patients. The present study elucidates the functional role of the differentiated embryonic chondrocyte-expressed gene 1 (DEC1) in promoting BC-related bone metastasis. Analysis of patient-derived samples and public databases revealed a significant upregulation of DEC1 and CXCR4 in breast tumors compared with adjacent normal tissues, with elevated levels correlating with increased metastatic potential, suggesting their synergistic involvement in BC progression. Intracardiac injection experiments demonstrated that Dec1-WT 4T1 cells induced more severe osteolysis and larger metastatic lesions than Dec1-KD 4T1 cells. In MDA-MB-231 cells, DEC1 overexpression (OE) upregulated CXCR4 and proliferation/migration-related genes, whereas DEC1 knockdown reversed these effects. Notably, AMD3100, a specific CXCR4 antagonist, partially reversed the DEC1-OE-induced upregulation of CXCR4 and associated pro-metastatic genes. Mechanistically, DEC1 bound to the CXCR4 promoter region (−230 to −326) and activated its transcription, corroborated by ChIP-seq data. Furthermore, pharmacological inhibition of AKT (LY294002) or JAK2 (AZD1480), but not ERK (PD98059), attenuated DEC1-mediated CXCR4 upregulation, although all three inhibitors mitigated DEC1-driven migration-related gene expression. Additionally, DEC1 enhanced CXCL12 secretion from mesenchymal stromal cells and osteoblasts, amplifying the CXCR4/CXCL12 axis within the bone microenvironment. Collectively, our findings demonstrate that DEC1 promotes BC bone metastasis by directly transactivating CXCR4 expression, providing a molecular basis for targeting DEC1 to prevent and treat BC bone metastasis.

Keywords

breast cancer bone metastasis / differentiated embryonic chondrocyte expressed gene 1 / CXCR4

Fundings

This work was supported by the Natural Science Foundation of China (Grant Nos. 82073934 and 81872937) and Office of Jiangsu Provincial Academic Degrees Committee (Grant No. JX10114120).

Acknowledgments

We thank Dr. Yan for providing a series of DEC1 plasmids.

References

[1] Trayes KP, Cokenakes SEH. Breast cancer treatment[J]. Am Fam Physician, 2021, 104(2): 171-178. https://pubmed.ncbi.nlm.nih.gov/34383430/

[2] Grabinski VF, Brawley OW. Disparities in breast cancer[J]. Obstet Gynecol Clin North Am, 2022, 49(1): 149-165. doi: 10.1016/j.ogc.2021.11.010

[3] Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: A fatal attraction[J]. Nat Rev Cancer, 2011, 11(6): 411-25. doi: 10.1038/nrc3055

[4] Wang R, Zhu Y, Liu X, et al. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage Ⅳ breast cancer[J]. BMC Cancer, 2019, 19(1): 1091. doi: 10.1186/s12885-019-6311-z

[5] Suvannasankha A, Chirgwin JM. Role of bone-anabolic agents in the treatment of breast cancer bone metastases[J]. Breast Cancer Res, 2014, 16(6): 484. doi: 10.1186/s13058-014-0484-9

[6] Kapoor R, Saxena AK, Vasudev P, et al. Cancer induced bone pain: Current management and future perspectives[J]. Med Oncol, 2021, 38(11): 134. doi: 10.1007/s12032-021-01587-7

[7] Ma J, Li J, Wang Y, et al. WSZG inhibits BMSC-induced EMT and bone metastasis in breast cancer by regulating TGF-β1/Smads signaling[J]. Biomed Pharmacother, 2020, 121: 109617. doi: 10.1016/j.biopha.2019.109617

[8] Demirkan B. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: Potential targets for prevention and treatment[J]. J Clin Med, 2013, 2(4): 264-282. doi: 10.3390/jcm2040264

[9] Zhang W, Bado I, Wang H, et al. Bone metastasis: Find your niche and fit in[J]. Trends Cancer, 2019, 5(2): 95-110. doi: 10.1016/j.trecan.2018.12.004

[10] Izraely S, Witz IP. Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment[J]. Int J Cancer, 2021, 148(6): 1308-1322. doi: 10.1002/ijc.33247

[11] Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410(6824): 50-56. doi: 10.1038/35065016

[12] Yang M, Zeng C, Li P, et al. Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells[J]. Onco Targets Ther, 2019, 12: 3849-3858. doi: 10.2147/OTT.S195661

[13] Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell, 1998, 93(2): 165-176. doi: 10.1016/S0092-8674(00)81569-X

[14] Meulmeester E, Ten Dijke P. The dynamic roles of TGF-β in cancer[J]. J Pathol, 2011, 223(2): 206-219. doi: 10.1002/path.2785

[15] Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer[J]. J Clin Oncol, 2010, 28(6): 1075-1083. doi: 10.1200/JCO.2009.25.3641

[16] Song X, Wei C, Li X. The signaling pathways associated with breast cancer bone metastasis[J]. Front Oncol, 2022, 12: 855609. doi: 10.3389/fonc.2022.855609

[17] Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases (Review)[J]. Int J Mol Med, 2017, 40(3): 587-606. doi: 10.3892/ijmm.2017.3071

[18] Yin X, Teng X, Ma T, et al. RUNX2 recruits the NuRD(MTA1)/CRL4B complex to promote breast cancer progression and bone metastasis[J]. Cell Death Differ, 2022, 29(11): 2203-2217. doi: 10.1038/s41418-022-01010-2

[19] Abudourousuli A, Chen S, Hu Y, et al. NKX2-8/PTHrP axis-mediated osteoclastogenesis and bone metastasis in breast cancer[J]. Front Oncol, 2022, 12: 907000. doi: 10.3389/fonc.2022.907000

[20] You J, Lin L, Liu Q, et al. The correlation between the expression of differentiated embryo-chondrocyte expressed gene l and oral squamous cell carcinoma[J]. Eur J Med Res, 2014, 19(1): 21. doi: 10.1186/2047-783X-19-21

[21] Gallo C, Fragliasso V, Donati B, et al. The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1[J]. Cell Death Dis, 2018, 9(9): 871. doi: 10.1038/s41419-018-0933-y

[22] Liu Y, Miao Y, Wang J, et al. DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1[J]. Int J Mol Med, 2013, 31(4): 855-860. doi: 10.3892/ijmm.2013.1279

[23] Jia Y, Liu Y, Zhu J, et al. DEC1 promotes progression of Helicobacter pylori-positive gastric cancer by regulating Akt/NF-κB pathway[J]. J Cell Mol Med, 2022, 26(7): 1943-1954. doi: 10.1111/jcmm.17219

[24] Lin L, Qiang Z, Chen K, et al. DEC1 deficiency protects against bone loss induced by ovariectomy by inhibiting inflammation[J]. J Biomed Res, 2024, 38(6): 613-627. doi: 10.7555/JBR.38.20240069

[25] Xu M, Zhang L, Lin L, et al. Cisplatin increases carboxylesterases through increasing PXR mediated by the decrease of DEC1[J]. J Biomed Res, 2023, 37(6): 431-447. doi: 10.7555/JBR.37.20230047

[26] Li S, Peng D, Yin Z, et al. Effect of DEC1 on the proliferation, adhesion, invasion and epithelial-mesenchymal transition of osteosarcoma cells[J]. Exp Ther Med, 2020, 19(3): 2360-2366. doi: 10.3892/etm.2020.8459

[27] Hu J, Mao Z, He S, et al. Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling pathway[J]. Biochem Pharmacol, 2017, 136: 109-121. doi: 10.1016/j.bcp.2017.04.010

[28] Zhu Q, Shan C, Li L, et al. Differential expression of genes associated with hypoxia pathway on bone marrow stem cells in osteoporosis patients with different bone mass index[J]. Ann Transl Med, 2019, 7(14): 309. doi: 10.21037/atm.2019.06.27

[29] He S, Guan Y, Wu Y, et al. DEC1 deficiency results in accelerated osteopenia through enhanced DKK1 activity and attenuated PI3KCA/Akt/GSK3β signaling[J]. Metabolism, 2021, 118: 154730. doi: 10.1016/j.metabol.2021.154730

[30] Yip RKH, Rimes JS, Capaldo BD, et al. Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis[J]. Nat Commun, 2021, 12(1): 6920. doi: 10.1038/s41467-021-26556-6

[31] Park PJ. ChIP-seq: advantages and challenges of a maturing technology[J]. Nat Rev Genet, 2009, 10(10): 669-680. doi: 10.1038/nrg2641

[32] Kidder BL, Hu G, Zhao K. ChIP-Seq: Technical considerations for obtaining high-quality data[J]. Nat Immunol, 2011, 12(10): 918-922. doi: 10.1038/ni.2117

[33] Yu G, Wang L, He Q. ChIPseeker: An R/Bioconductor package for ChIP peak annotation, comparison and visualization[J]. Bioinformatics, 2015, 31(14): 2382-2383. doi: 10.1093/bioinformatics/btv145

[34] Yi Y, Liao B, Zheng Z, et al. Downregulation of DEC1 inhibits proliferation, migration and invasion, and induces apoptosis in ovarian cancer cells via regulation of Wnt/β-catenin signaling pathway[J]. Exp Ther Med, 2021, 21(4): 372. doi: 10.3892/etm.2021.9803

[35] Hankins ML, Smith CN, Hersh B, et al. Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases[J]. J Bone Oncol, 2021, 29: 100363. doi: 10.1016/j.jbo.2021.100363

[36] Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: Clinical and experimental perspectives[J]. Int J Mol Sci, 2019, 20(9): 2272. doi: 10.3390/ijms20092272

[37] Yin J, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone[J]. Cell Res, 2005, 15(1): 57-62. doi: 10.1038/sj.cr.7290266

[38] Wang S, Li G, Tan C, et al. FOXF2 reprograms breast cancer cells into bone metastasis seeds[J]. Nat Commun, 2019, 10(1): 2707. doi: 10.1038/s41467-019-10379-7

[39] Du Y, Yan W, Wang Z, et al. Lanostane inhibits the proliferation and bone metastasis of human breast cancer cells via inhibition of Rho-associated kinase signaling[J]. J BUON, 2020, 25(3): 1323-1329. https://pubmed.ncbi.nlm.nih.gov/32862572/

[40] Mohammadi Ghahhari N, Sznurkowska MK, Hulo N, et al. Cooperative interaction between ERα and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis[J]. Nat Commun, 2022, 13(1): 2104. doi: 10.1038/s41467-022-29723-5

[41] Puppo M, Valluru MK, Croset M, et al. MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness[J]. Br J Cancer, 2023, 129(5): 754-771. doi: 10.1038/s41416-023-02340-9

[42] Lin Q, Fang X, Liang G, et al. Silencing CTNND1 mediates triple-negative breast cancer bone metastasis via upregulating CXCR4/CXCL12 axis and neutrophils infiltration in bone[J]. Cancers (Basel), 2021, 13(22): 5703. doi: 10.3390/cancers13225703

[43] Jekabsons MB, Merrell M, Skubiz AG, et al. Breast cancer cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells[J]. Cancer Metab, 2023, 11(1): 4. doi: 10.1186/s40170-023-00303-5

[44] Li Y, Xie M, Yang J, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter[J]. Oncogene, 2006, 25(23): 3296-3306. doi: 10.1038/sj.onc.1209363

[45] Ning R, Zhan Y, He S, et al. Interleukin-6 induces DEC1, promotes DEC1 interaction with RXRα and suppresses the expression of PXR, CAR and their target genes[J]. Front Pharmacol, 2017, 8: 866. doi: 10.3389/fphar.2017.00866

[46] Yin X, Liu Z, Zhu P, et al. CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway[J]. J Cell Biochem, 2019, 120(6): 9724-9736. doi: 10.1002/jcb.28253

[47] Zhang W, Zhang R, Ge Y, et al. S100a16 deficiency prevents hepatic stellate cells activation and liver fibrosis via inhibiting CXCR4 expression[J]. Metabolism, 2022, 135: 155271. doi: 10.1016/j.metabol.2022.155271

[48] Jiang W, Zhang J, Zhang X, et al. VAP-PLGA microspheres (VAP-PLGA) promote adipose-derived stem cells (ADSCs)-induced wound healing in chronic skin ulcers in mice via PI3K/Akt/HIF-1α pathway[J]. Bioengineered, 2021, 12(2): 10264-10284. doi: 10.1080/21655979.2021.1990193

[49] Liu Y, Liu N, Li X, et al. Ginsenoside Rb1 Modulates the migration of bone-derived mesenchymal stem cells through the SDF-1/CXCR4 axis and PI3K/Akt pathway[J]. Dis Markers, 2022, 2022: 5196682. doi: 10.1155/2022/5196682

[50] Shen C, Li J, Li R, et al. Effects of tumor-derived DNA on CXCL12-CXCR4 and CCL21-CCR7 axes of hepatocellular carcinoma cells and the regulation of sinomenine hydrochloride[J]. Front Oncol, 2022, 12: 901705. doi: 10.3389/fonc.2022.901705

[51] Abdelouahab H, Zhang Y, Wittner M, et al. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner[J]. Oncotarget, 2017, 8(33): 54082-54095. doi: 10.18632/oncotarget.10789

[52] Corrigan M, Shields C, O'Leary D, et al. Hypertonic saline attenuates the pro-metastatic effects of LPS by reducing tumor cell migration, proliferation and MMP-9 expression[J]. World J Oncol, 2011, 2(6): 289-297. https://www.wjon.org/index.php/wjon/article/view/420